The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.

ABSTRACT:

Introduction

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patients with CHF.

Methods

In a double-blind, randomised (2:1), placebo-controlled, parallel-group, clinical trial, 74 patients with NYHA class II-III CHF and an ejection fraction of 49% or less received empagliflozin 10 mg once daily or placebo for 3 months. In each patient, tissue sodium content of the lower leg was assessed non-invasively by sodium-MRI (²³Na-MRI) at baseline, after 1 and 3 months of treatment.

Results

After 1 and 3 months treatment with empagliflozi

SUBMITTER: Kolwelter J 

PROVIDER: S-EPMC9849317 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature